Admission Date:  [**2110-9-23**]              Discharge Date:   [**2110-9-24**]

Date of Birth:  [**2038-6-5**]             Sex:   M

Service: MEDICINE

Allergies:
Patient recorded as having No Known Allergies to Drugs

Attending:[**First Name3 (LF) 106**]
Chief Complaint:
dyspnea

Major Surgical or Invasive Procedure:
none

History of Present Illness:
Mr. [**Known lastname 3646**] is a 71 year old man with a history of diastolic heart
failure (EF 40-45%), critical aortic stenosis, multiple myeloma,
amyloidosis, and chronic renal insufficiency who presents with
exertional dyspnea worsening over the last 2 weeks or so. He has
noticed increased abdominal girth over this period, without any
abdominal discomfort. He has had some associated poor energy,
limited appetite, and nausea. He vomited once yesterday, and has
had some loose stools without melena or hematochezia. He thinks
he has gained weight but is unsure of the amount. He can ascend
[**1-28**] flights of stairs before having to stop due to dyspnea which
he says is his baseline. His wife however notes that he seems
out of breath just walking across a small room. He has stable 3
pillow orthopnea, but denies any PND. He denies any difficulties
with taking his medications as prescribed, or any increased salt
intake. He denies fevers, chills, sweats, palpitations,
lightheadedness/fainting, chest discomfort, wheezing, leg pains
or history of thrombosis. He does have a chronic cough not
recently worse productive of white sputum, without any
hemoptysis.
.
In the ED, his triage vitals were T98.1, P 98, Bp 104/64, RR 18,
99% on RA. He received 80mg lasix IV x1. On the floor, he was
noted to be "extremely short of breath" tachypneic to the 30's
and wheezing with O2 saturation dipping to 79. He was placed on
a non-rebreather facemask, given 2mg morphine, started on a
nitroglycerin drip, and subsequently transferred to the CCU.

Past Medical History:
CHF EF 40-45%, diastolic HF
AS - valve area <0.8cm2 on [**2110-8-25**] echo
CAD
DM2
HTN
CKD
Hyperlipidemia
Left atrial appendage thrombus

Social History:
The patient is married, lives with wife has children. Retired
from working for Polaroid. Social history is significant for the
absence of current tobacco use, previous use x 50 years, quit 5
years ago. There is no history of alcohol abuse. There is no
family history of premature coronary artery disease or sudden
death.

Family History:
M: suicide. F: died at age 51, is unsure of what cause. No
family
history of premature coronary artery disease or sudden death.

Physical Exam:
T101.8 P 132 BP 108/55 RR 22 O2 100% on nonrebreather
General: Thin elderly man in mild respiratory distress. Able to
speak in short sentences
Neck: JVP 10cm. Carotid upstroke brisk bilaterally
Pulm: Lungs with slightly decreased breath sounds on R, +wheezes
without rales
CV: Regular rate S1 S2 II/VI SEM base
Abd: Soft +BS, +fluid wave, nontender
Extrem: Warm, well perfused with 1+ pitting edema. 2+ distal
pulses bilaterally.
Neuro: Alert and oriented
Lines: Has R PICC

Pertinent Results:
[**2110-9-23**] 11:46AM   WBC-15.0*# RBC-3.17* HGB-10.5* HCT-33.0*
MCV-104* MCH-33.1* MCHC-31.8 RDW-17.3*
[**2110-9-23**] 11:46AM   PLT SMR-NORMAL PLT COUNT-184
[**2110-9-23**] 11:46AM   NEUTS-93* BANDS-3 LYMPHS-1* MONOS-3 EOS-0
BASOS-0 ATYPS-0 METAS-0 MYELOS-0
[**2110-9-23**] 11:46AM   PT-29.8* PTT-33.9 INR(PT)-3.1*
[**2110-9-23**] 11:46AM   ALBUMIN-3.3* CALCIUM-9.3
[**2110-9-23**] 11:46AM   proBNP-[**Numeric Identifier 71895**]*
[**2110-9-23**] 11:46AM   ALT(SGPT)-90* AST(SGOT)-167* ALK PHOS-236*
AMYLASE-110* TOT BILI-2.4*
[**2110-9-23**] 11:46AM   GLUCOSE-99 UREA N-52* CREAT-2.7* SODIUM-131*
POTASSIUM-4.1 CHLORIDE-96 TOTAL CO2-24 ANION GAP-15
[**2110-9-23**] 12:45PM URINE  COLOR-Yellow APPEAR-Clear SP [**Last Name (un) 155**]-1.011
[**2110-9-23**] 12:45PM URINE  BLOOD-TR NITRITE-NEG PROTEIN-TR
GLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.0
LEUK-NEG
[**2110-9-23**] 12:45PM URINE  RBC-0 WBC-[**3-31**] BACTERIA-RARE YEAST-NONE
EPI-0-2
[**2110-9-23**] 06:42PM   LACTATE-10.6*
.
CXR [**9-23**]
Right-sided pleural effusion, possibly slightly decreased in
size compared to the previous study. Patchy density at the right
lung base likely reflects atelectasis.
.
RUQ Ultrasound [**9-23**]
IMPRESSION: Moderate to large ascites with no ultrasound
evidence suggestive of acute cholecystitis. There is, however
re-demonstration of previously noted gallbladder sludge.
Moderate to large amount of ascites again noted. Doppler
waveform consistent with right heart failure.
.
EKG [**9-23**]
Sinus rhythm 94bpm. Upper limits of normal rate. P-R interval
prolongation. Marked left axis deviation. Low voltage
throughout. Borderline intraventricular conduction delay. Late R
wave progression. ST-T wave abnormalities. Since the previous
tracing of [**2110-8-27**] probably no significant change. Clinical
correlation is suggested.
.
Renal Ultrasound [**9-24**]
1. Limited. Right kidney not visualized. The left kidney appears
normal.
2. Abundant ascites.
.
MICROBIOLOGY
[**2110-9-23**] 9:14 pm BLOOD CULTURE      Source: Line-PICC SET #2.

                            **FINAL REPORT [**2110-9-28**]**

   AEROBIC BOTTLE (Final [**2110-9-27**]):
      REPORTED BY PHONE TO FA6B [**Last Name (NamePattern4) 71896**] [**2110-9-24**] 930AM.
      ESCHERICHIA COLI.    FINAL SENSITIVITIES.
      PSEUDOMONAS AERUGINOSA.    FINAL SENSITIVITIES.
      STAPHYLOCOCCUS, COAGULASE NEGATIVE.    FINAL
SENSITIVITIES.
         Staphylococcus species may develop resistance during
prolonged
         therapy with quinolones.   Therefore, isolates that are
initially
         susceptible may become resistant within three to four
days after
         initiation of therapy.  Testing of repeat isolates may
be
         warranted.

                              SENSITIVITIES: MIC expressed in
MCG/ML

_________________________________________________________
                             ESCHERICHIA COLI
                             |          PSEUDOMONAS AERUGINOSA
                             |          |
STAPHYLOCOCCUS, COAGULASE N
                             |          |          |
AMPICILLIN------------  =>32 R
AMPICILLIN/SULBACTAM--     8 S
CEFAZOLIN-------------   <=4 S
CEFEPIME--------------   <=1 S        2 S
CEFTAZIDIME-----------   <=1 S        4 S
CEFTRIAXONE-----------   <=1 S
CEFUROXIME------------     4 S
CIPROFLOXACIN---------<=0.25 S   <=0.25 S
CLINDAMYCIN-----------                      <=0.25 S
ERYTHROMYCIN----------                      <=0.25 S
GENTAMICIN------------   <=1 S      <=1 S    <=0.5 S
IMIPENEM--------------   <=1 S      <=1 S
LEVOFLOXACIN----------                      <=0.12 S
MEROPENEM-------------<=0.25 S   <=0.25 S
OXACILLIN-------------                      <=0.25 S
PENICILLIN------------                       =>0.5 R
PIPERACILLIN----------              <=4 S
PIPERACILLIN/TAZO-----   <=4 S        8 S
TOBRAMYCIN------------   <=1 S      <=1 S
TRIMETHOPRIM/SULFA----  =>16 R

   ANAEROBIC BOTTLE (Final [**2110-9-27**]):
      ESCHERICHIA COLI.
         IDENTIFICATION AND SENSITIVITIES PERFORMED FROM AEROBIC
BOTTLE.
      PSEUDOMONAS AERUGINOSA.
         IDENTIFICATION AND SENSITIVITIES PERFORMED FROM AEROBIC
BOTTLE.
      STAPHYLOCOCCUS, COAGULASE NEGATIVE.
         SENSITIVITIES PERFORMED FROM AEROBIC BOTTLE.
 AEROBIC BOTTLE (Final [**2110-9-27**]):
      REPORTED BY PHONE TO FA6B [**Last Name (NamePattern4) 71896**] [**2110-9-24**] 930AM.
      ESCHERICHIA COLI.
         IDENTIFICATION AND SENSITIVITIES PERFORMED ON CULTURE #
236-2195B
         [**2110-9-23**].
      PSEUDOMONAS AERUGINOSA.
         SENSITIVITIES PERFORMED ON CULTURE # 236-2195B [**2110-9-23**].

      STAPHYLOCOCCUS, COAGULASE NEGATIVE.    FINAL
SENSITIVITIES.
         Staphylococcus species may develop resistance during
prolonged
         therapy with quinolones.   Therefore, isolates that are
initially
         susceptible may become resistant within three to four
days after
         initiation of therapy.  Testing of repeat isolates may
be
         warranted.

                              SENSITIVITIES: MIC expressed in
MCG/ML

_________________________________________________________
